As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance.

EndNote Style
Therapy options for psychiatric disorders in pregnancy
While psychotherapy is often preferred in treating mild psychiatric disorders, drug and other non-drug options are adopted in treating moderate and severe conditions during pregnancy. In addition, cognitive behavioral therapy (CBT) has become prominent among psychotherapies. Regarding antidepressants, Sertraline, Citalopram, and Escitalopram are recommended as the first choices. Benzodiazepines are not recommended unless necessary; they are prescribed in the minimum dose and duration if highly needed. Mood stabilizers are considered risky and should be carefully used. Moreover, the expectant mother should be required for fetal follow-up more frequently and in detail when such drugs are prescribed. The safest among them is considered Lamotrigine. If antipsychotics are to be prescribed, the expectant mother’s blood glucose, weight, and blood pressure should be followed up frequently. Due to the possible side effects to occur in the infant following delivery, antipsychotics may be considered to be discontinued immediately before birth and restarted after delivery. It is argued that there is no notable difference between the first and second generations. Besides, electroconvulsive therapy (ECT) is recommended in cases of suicidal depression, manic attack, psychotic attack, and catatonia where rapid response is required. Although promising results were previously reported about transcranial magnetic stimulation (TMS) and bright light therapy, their utilization areas are still limited.

1. Langan R, Goodbred AJ. Identification and Management of PeripartumDepression.Am Fam Physician. 2016;93(10):852-858.
2. Soufia M, Aoun J, Gorsane MA, Krebs MO. ISRS et grossesse: revue de lalittérature [SSRIs and pregnancy: a review of the literature].Encephale.2010;36(6):513-516. doi:10.1016/j.encep.2010.02.003
3. Shen ZQ, Gao SY, Li SX, et al. Sertraline use in the first trimester andrisk of congenital anomalies: a systemic review and meta-analysis ofcohort studies.Br J Clin Pharmacol. 2017;83(4):909-922. doi:10.1111/bcp.13161
4. Eke AC, Saccone G, Berghella V. Selective serotonin reuptakeinhibitor (SSRI) use during pregnancy and risk of preterm birth: asystematic review and meta-analysis.BJOG. 2016;123(12):1900-1907.doi:10.1111/1471-0528.14144
5. Uguz F. The Use of Antidepressant Medications DuringPregnancy and the Risk of Neonatal Seizures: A SystematicReview.J Clin Psychopharmacol. 2019;39(5):479-484. doi:10.1097/JCP.0000000000001093
6. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetineuse and the prevalence of congenital, specifically cardiac, defects: ameta-analysis of epidemiological studies.Birth Defects Res A Clin MolTeratol. 2010;88(3):159-170. doi:10.1002/bdra.20627
7. Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants,Antipsychotics, and Mood Stabilizers in Pregnancy: What Do We Knowand How Should We Treat Pregnant Women with Depression.BirthDefects Res. 2017;109(12):933-956. doi:10.1002/bdr2.1079
8. Smit M, Dolman KM, Honig A. Mirtazapine in pregnancy and lactation- A systematic review.Eur Neuropsychopharmacol. 2016;26(1):126-135.doi:10.1016/j.euroneuro.2015.06.014
9. Lassen D, Ennis ZN, Damkier P. First-Trimester Pregnancy Exposureto Venlafaxine or Duloxetine and Risk of Major CongenitalMalformations: A Systematic Review.Basic Clin Pharmacol Toxicol.2016;118(1):32-36. doi:10.1111/bcpt.12497
10. Nordeng H, Bergsholm YK, Bøhler E, Spigset O. Overgang av selektiveserotoninreopptakshemmere til morsmelk [The transfer of selectiveserotonin reuptake inhibitors to human milk].Tidsskr Nor Laegeforen.2001;121(2):199-203.
11. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J,Hertzman C. Major congenital malformations following prenatalexposure to serotonin reuptake inhibitors and benzodiazepines usingpopulation-based health data.Birth Defects Res B Dev Reprod Toxicol.2008;83(1):68-76. doi:10.1002/bdrb.20144
12. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Useof benzodiazepines and benzodiazepine receptor agonistsduring pregnancy: neonatal outcome and congenitalmalformations.Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210.doi:10.1002/pds.1457
13. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternallorazepam on the neonate.Br Med J (Clin Res Ed). 1981;282(6270):1106-1108. doi:10.1136/bmj.282.6270.1106
14. Bellantuono C, Martellini M, Orsolini L. Benzodiazepines and Z-Drugsin Pregnancy. In Perinatal Psychopharmacology. Springer, Cham. 2019;203-10.
15. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, EinarsonTR. Benzodiazepine use in pregnancy and major malformations ororal cleft: meta-analysis of cohort and case-control studies.BMJ.1998;317(7162):839-843. doi:10.1136/bmj.317.7162.839
16. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepineexposure in pregnancy and risk of major malformations: a criticaloverview.Gen Hosp Psychiatry. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003
17. Creeley CE, Denton LK. Use of Prescribed Psychotropics duringPregnancy: A Systematic Review of Pregnancy, Neonatal, andChildhood Outcomes.Brain Sci. 2019;9(9):235. Published 2019 Sep 14.doi:10.3390/brainsci9090235
18. Yakoob MY, Bateman BT, Ho E, et al. The risk of congenitalmalformations associated with exposure to β-blockers early inpregnancy: a meta-analysis.Hypertension. 2013;62(2):375-381.doi:10.1161/HYPERTENSIONAHA.111.00833
19. Davis RL, Eastman D, McPhillips H, et al. Risks of congenitalmalformations and perinatal events among infants exposed to calciumchannel and beta-blockers during pregnancy.Pharmacoepidemiol DrugSaf. 2011;20(2):138-145. doi:10.1002/pds.2068
20. Ersbøll AS, Hedegaard M, Søndergaard L, Ersbøll M, Johansen M.Treatment with oral beta-blockers during pregnancy complicatedby maternal heart disease increases the risk of fetal growthrestriction.BJOG. 2014;121(5):618-626. doi:10.1111/1471-0528.12522
21. Gonzalez-Estrada A, Geraci SA. Allergy Medications DuringPregnancy.Am J Med Sci. 2016;352(3):326-331. doi:10.1016/j.amjms.2016.05.030
22. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A; NationalBirth Defects Prevention Study. Use of antihistamine medicationsduring early pregnancy and isolated major malformations.BirthDefects Res A Clin Mol Teratol. 2009;85(2):137-150. doi:10.1002/bdra.20513
23. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restrictionand birth defects with newer and older antiepileptic drugs duringpregnancy.J Neurol. 2014;261(3):579-588. doi:10.1007/s00415-013-7239-x.
24. Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome followingmaternal exposure to pregabalin may call for concern.Neurology.2016;86(24):2251-2257. doi:10.1212/WNL.0000000000002767
25. Kozma C. Neonatal toxicity and transient neurodevelopmental deficitsfollowing prenatal exposure to lithium: Another clinical report anda review of the literature.Am J Med Genet A. 2005;132A(4):441-444.doi:10.1002/ajmg.a.30501
26. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy andbreastfeeding: focus on emerging mood stabilizers.Bipolar Disord.2006;8(3):207-220. doi:10.1111/j.1399-5618.2006.00295.x
27. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML.A reevaluation of risk of in utero exposure to lithium [publishedcorrection appears in JAMA 1994 May 18;271(19):1485].JAMA.1994;271(2):146-150.
28. Williams K, Oke S. Lithium and pregnancy. Psychiatric Bulletin 2000;24(6): 229-2.
29. Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review.Isr JPsychiatry Relat Sci. 2008;45(2):95-106.
30. Poels EMP, Bijma HH, Galbally M, Bergink V. Lithium duringpregnancy and after delivery: a review.Int J Bipolar Disord. 2018;6(1):26.Published 2018 Dec 2. doi:10.1186/s40345-018-0135-7
31. Akdeniz F. Gebelikte ve Doğum Sonrası Dönemde Bipolar Bozukluk.Gebelikte ve Doğum Sonrası Dönemde Ruhsal Bozuklukların SağaltımKılavuzu. 1. Baskı, Ankara: Türkiye Psikiyatri Derneği ÇalışmaBirimleri Dizisi; 2021.
32. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapyin pregnancy and major congenital malformations.N Engl J Med.2010;362(23):2185-2193. doi:10.1056/NEJMoa0907328
33. Epstein RA, Moore KM, Bobo WV. Treatment of bipolar disordersduring pregnancy: maternal and fetal safety and challenges.DrugHealthc Patient Saf. 2014;7:7-29. Published 2014 Dec 24. doi:10.2147/DHPS.S50556
34. Akdeniz F. Gebelik ve Emzirme Döneminde Psikotrop İlaç Kullanımı.Temel Psikofarmakoloji. Ankara: Türkiye Psikiyatri Derneği; 2010.
35. Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure tocarbamazepine and specific congenital malformations: systematicreview and case-control study.BMJ. 2010;341:c6581. Published 2010Dec 2. doi:10.1136/bmj.c6581
36. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs.LancetNeurol. 2012;11(9):803-813. doi:10.1016/S1474-4422(12)70103-5
37. Vitale SG, Laganà AS, Muscatello MR, et al. Psychopharmacotherapyin Pregnancy and Breastfeeding.Obstet Gynecol Surv. 2016;71(12):721-733. doi:10.1097/OGX.0000000000000369
38. Gentile S. Antipsychotic therapy during early and late pregnancy. Asystematic review.Schizophr Bull. 2010;36(3):518-544. doi:10.1093/schbul/sbn107
39. Einarson A, Boskovic R. Use and safety of antipsychotic drugs duringpregnancy.J Psychiatr Pract. 2009;15(3):183-192. doi:10.1097/01.pra.0000351878.45260.94
40. Reis M, Källén B. Maternal use of antipsychotics in early pregnancyand delivery outcome.J Clin Psychopharmacol. 2008;28(3):279-288.doi:10.1097/JCP.0b013e318172b8d5
41. Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy:a review of their maternal and fetal effects.Ther Adv Drug Saf.2014;5(2):100-109. doi:10.1177/2042098614522682
42. McAllister-Williams RH, Baldwin DS, Cantwell R, et al. BritishAssociation for Psychopharmacology consensus guidance onthe use of psychotropic medication preconception, in pregnancyand postpartum 2017.J Psychopharmacol. 2017;31(5):519-552.doi:10.1177/0269881117699361
43. Petersen I, McCrea RL, Sammon CJ, et al. Risks and benefits ofpsychotropic medication in pregnancy: cohort studies based onUK electronic primary care health records.Health Technol Assess.2016;20(23):1-176. doi:10.3310/hta20230
44. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. PregnancyOutcomes Following In Utero Exposure to Second-GenerationAntipsychotics: A Systematic Review and Meta-Analysis.JClin Psychopharmacol. 2015;35(5):559-565. doi:10.1097/JCP.0000000000000391
45. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychoticadministration during late pregnancy: placental passage and obstetricaloutcomes.Am J Psychiatry. 2007;164(8):1214-1220. doi:10.1176/appi.ajp.2007.06111886
46. Stephens S, Ford E, Paudyal P, Smith H. Effectiveness of PsychologicalInterventions for Postnatal Depression in Primary Care: A Meta-Analysis.Ann Fam Med. 2016;14(5):463-472. doi:10.1370/afm.1967
47. UK ECT Review Group. Efficacy and safety of electroconvulsive therapyin depressive disorders: a systematic review and meta-analysis.Lancet.2003;361(9360):799-808. doi:10.1016/S0140-6736(03)12705-5
48. Ward HB, Fromson JA, Cooper JJ, De Oliveira G, Almeida M.Recommendations for the use of ECT in pregnancy: literature reviewand proposed clinical protocol [published correction appears in ArchWomens Ment Health. 2018 Jun 23;:].Arch Womens Ment Health.2018;21(6):715-722. doi:10.1007/s00737-018-0851-0
49. Hızlı Sayar G. Gebelikte ve Doğum Sonrası Dönemde TranskranialManyetik Uyarım Tedavisi. Gebelikte ve Doğum Sonrası DönemdeRuhsal Bozuklukların Sağaltım Kılavuzu. 1. Baskı, Ankara: TürkiyePsikiyatri Derneği Çalışma Birimleri Dizisi; 2021.
50. Vicario CM, Salehinejad MA, Felmingham K, Martino G, Nitsche MA.A systematic review on the therapeutic effectiveness of non-invasivebrain stimulation for the treatment of anxiety disorders.NeurosciBiobehav Rev. 2019;96:219-231. doi:10.1016/j.neubiorev.2018.12.012
Volume 1, Issue 1, 2023
Page : 21-25